Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model

Gemcitabine plus S-1 (GS) is commonly used to treat advanced pancreatic cancer (APC) in Asia. Few clinical experiments have demonstrated the clinical efficacy of GS in routine clinical practice. We aimed to identify the prognostic factors and develop a prognostic model for survival prediction in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Ching-Fu, Huang, Pei-Wei, Chen, Jen-Shi, Chen, Yen-Yang, Lu, Chang-Hsien, Chang, Pei-Hung, Hung, Yu-Shin, Chou, Wen-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356456/
https://www.ncbi.nlm.nih.gov/pubmed/30634387
http://dx.doi.org/10.3390/cancers11010057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356456/
https://www.ncbi.nlm.nih.gov/pubmed/30634387
http://dx.doi.org/10.3390/cancers11010057

Ejemplares similares